# ADRD Classification - RAG Resources and Clinical Guidelines

This document provides references to authoritative clinical guidelines and resources for ADRD classification. Use these for RAG retrieval to enhance classification accuracy.

## ðŸ“š PRIMARY DIAGNOSTIC CRITERIA

### 1. NIA-AA Criteria for Alzheimer's Disease
**National Institute on Aging - Alzheimer's Association (2011, updated 2018)**

- **2011 Criteria**: McKhann et al. "The diagnosis of dementia due to Alzheimer's disease" *Alzheimer's & Dementia* 2011;7(3):263-269
  - Defines probable and possible AD dementia
  - Incorporates biomarkers (amyloid, tau, neurodegeneration)
  - Establishes clinical and research criteria

- **2018 Research Framework**: Jack et al. "NIA-AA Research Framework" *Alzheimer's & Dementia* 2018;14(4):535-562
  - A/T/N classification system
    - **A**: Amyloid biomarkers (PET, CSF AÎ²42)
    - **T**: Tau biomarkers (PET, CSF p-tau)
    - **N**: Neurodegeneration (MRI atrophy, FDG-PET hypometabolism)
  - Biological definition of Alzheimer's disease

**Key Points for Classification**:
- Insidious onset over months to years
- Clear-cut history of worsening cognition (by report or observation)
- Initial and most prominent cognitive deficits:
  - **Amnestic presentation** (most common): Memory impairment + â‰¥1 other domain
  - **Non-amnestic presentations**: Language, visuospatial, or executive dysfunction
- Diagnosis should not be applied when substantial concomitant cerebrovascular disease is present (mixed dementia if both)

### 2. DSM-5 Criteria for Major and Mild Neurocognitive Disorder
**American Psychiatric Association (2013)**

**Major Neurocognitive Disorder** (equivalent to dementia):
- Significant cognitive decline from previous level in â‰¥1 cognitive domain
- Cognitive deficits interfere with independence in everyday activities
- Not occurring exclusively in context of delirium
- Not better explained by another mental disorder

**Mild Neurocognitive Disorder** (similar to MCI):
- Modest cognitive decline from previous level
- Does NOT interfere with capacity for independence
- Not occurring exclusively during delirium
- Not better explained by another mental disorder

**Specify etiology**: AD, vascular, LBD, FTD, traumatic brain injury, substance use, HIV, prion, Parkinson's, Huntington's, other medical condition, multiple etiologies, unspecified

### 3. Vascular Dementia Criteria
**NINDS-AIREN Criteria** (Roman et al., *Neurology* 1993;43:250-260)

**Probable Vascular Dementia**:
- Dementia
- Cerebrovascular disease by clinical history, neurological signs, and/or brain imaging
- Relationship between dementia and CVD:
  - Onset within 3 months of recognized stroke
  - Abrupt deterioration or stepwise progression

**Features supporting diagnosis**:
- Early presence of gait disturbance
- History of unsteadiness, frequent falls
- Early urinary symptoms
- Pseudobulbar palsy
- Personality and mood changes

### 4. Lewy Body Dementia Consensus Criteria (2017)
**McKeith et al., *Neurology* 2017;89:88-100**

**Essential feature**: Progressive cognitive decline interfering with normal social/occupational function

**Core clinical features** (â‰¥2 for probable DLB, 1 for possible):
1. Fluctuating cognition with pronounced variations in attention and alertness
2. Recurrent visual hallucinations (well-formed, detailed)
3. REM sleep behavior disorder (may precede cognitive decline)
4. One or more features of parkinsonism

**Supportive features**:
- Severe neuroleptic sensitivity
- Postural instability, repeated falls
- Syncope, transient loss of consciousness
- Autonomic dysfunction
- Hypersomnia, hyposmia
- Hallucinations in other modalities
- Delusions, apathy, anxiety, depression

**Indicative biomarkers**:
- Reduced dopamine transporter uptake in basal ganglia (DaTscan)
- Low uptake MIBG myocardial scintigraphy
- REM sleep without atonia on PSG

### 5. Frontotemporal Dementia Criteria
**Rascovsky et al., *Brain* 2011;134:2456-2477**

**Behavioral variant FTD** (bvFTD) - requires 3 of 6:
1. Early behavioral disinhibition
2. Early apathy or inertia
3. Early loss of sympathy or empathy
4. Early perseverative, stereotyped, or compulsive behavior
5. Hyperorality and dietary changes
6. Executive deficits with relative sparing of memory and visuospatial

**Language variants**:
- **Semantic dementia**: Loss of word meaning, surface dyslexia
- **Progressive non-fluent aphasia**: Effortful speech, agrammatism, apraxia of speech

---

## ðŸ§ª COGNITIVE ASSESSMENT GUIDELINES

### Mini-Mental State Examination (MMSE)
**Folstein et al., *J Psychiatr Res* 1975;12:189-198**

**Scoring**:
- 24-30: Normal or mild impairment
- 18-23: Mild dementia
- 10-17: Moderate dementia
- 0-9: Severe dementia

**Considerations**:
- Affected by age, education, language, cultural background
- Ceiling effect (less sensitive to mild impairment)
- Add 1 point if education <9 years

### Montreal Cognitive Assessment (MoCA)
**Nasreddine et al., *J Am Geriatr Soc* 2005;53:695-699**

**Scoring**:
- â‰¥26: Normal (with education correction)
- 18-25: Mild cognitive impairment
- <18: Dementia range

**Education correction**: Add 1 point if â‰¤12 years education (maximum score 30)

**Advantages over MMSE**:
- More sensitive for MCI detection
- Better assessment of executive function, attention, abstraction
- Less ceiling effect

### Clinical Dementia Rating (CDR)
**Morris, *Neurology* 1993;43:2412-2414**

**Global CDR Score**:
- 0: No impairment
- 0.5: Questionable/Very mild dementia
- 1: Mild dementia
- 2: Moderate dementia
- 3: Severe dementia

**Domains assessed**:
- Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, Personal Care

**CDR Sum of Boxes** (CDR-SB): Sum of domain scores (0-18), more sensitive to change than global score

---

## ðŸ§¬ BIOMARKER INTERPRETATION GUIDELINES

### CSF Biomarkers for Alzheimer's Disease
**Hansson et al., *Lancet Neurol* 2018;17:661-670**

**AD CSF Profile**:
- **Low AÎ²42** (or low AÎ²42/AÎ²40 ratio): Amyloid pathology
- **High total tau (t-tau)**: Neuronal damage
- **High phosphorylated tau (p-tau)**: Tau pathology

**Cut-offs** (vary by assay, laboratory):
- AÎ²42 <550 pg/mL (or AÎ²42/AÎ²40 ratio <0.09)
- t-tau >350 pg/mL
- p-tau >60 pg/mL

**Interpretation**:
- AD: Low AÎ²42 + High tau (both t-tau and p-tau)
- Non-AD neurodegeneration: Normal AÎ²42 + High t-tau
- Normal aging: Normal all markers

### Amyloid PET Imaging
**Johnson et al., *Alzheimer's Dement* 2013;9:e1-16**

**Tracers**: Florbetapir (Amyvid), Florbetaben (Neuraceq), Flutemetamol (Vizamyl), Pittsburgh Compound-B (PiB)

**Interpretation**:
- **Positive scan**: Moderate to frequent amyloid plaques (consistent with AD neuropathological change)
- **Negative scan**: No or sparse plaques (AD neuropathological change not present)

**Clinical use**:
- Does NOT diagnose AD dementia alone (amyloid can be present in normal aging)
- Helps rule out AD in uncertain cases
- Useful in atypical presentations, early-onset dementia (<65)

### Tau PET Imaging
**Ossenkoppele et al., *JAMA* 2016;315:2340-2349**

**Tracers**: Flortaucipir (Tauvid), others in development

**Patterns**:
- **AD**: Widespread cortical tau, temporoparietal predominance
- **Non-AD**: Different distribution patterns (e.g., basal ganglia in PSP)

**Clinical utility**:
- More specific for AD than amyloid PET
- Correlates better with cognitive symptoms than amyloid

### FDG-PET (Fluorodeoxyglucose PET)
**Silverman et al., *J Alzheimers Dis* 2001;3:265-283**

**AD pattern**: Temporo-parietal and posterior cingulate hypometabolism

**Other patterns**:
- **FTD**: Frontal and/or temporal hypometabolism
- **DLB**: Posterior cortical hypometabolism (similar to AD) + relative preservation of occipital lobe
- **VaD**: Patchy, irregular hypometabolism

---

## ðŸ“Š FUNCTIONAL ASSESSMENT SCALES

### Katz Index of Independence in Activities of Daily Living
**Katz et al., *JAMA* 1963;185:914-919**

**Assesses 6 basic ADLs**:
- Bathing, Dressing, Toileting, Transferring, Continence, Feeding

**Scoring**: Independent (1) vs Dependent (0) for each activity

### Lawton Instrumental Activities of Daily Living (IADL) Scale
**Lawton & Brody, *Gerontologist* 1969;9:179-186**

**Assesses 8 IADLs**:
- Phone use, Shopping, Food preparation, Housekeeping, Laundry, Transportation, Medications, Finances

**Scoring**: Independent (1) vs Dependent (0) for each

**Clinical significance**:
- IADL impairment occurs earlier than ADL impairment in dementia
- Preserved ADLs with impaired IADLs â†’ Mild dementia or advanced MCI
- ADL impairment â†’ Moderate to severe dementia

### Functional Activities Questionnaire (FAQ)
**Pfeffer et al., *J Gerontol* 1982;37:323-329**

**10 items assessing IADLs**:
0 = normal, 1 = has difficulty but does by self, 2 = requires assistance, 3 = dependent

**Scoring**: Sum (0-30)
- 0-5: Normal
- 6-8: Questionable impairment
- â‰¥9: Impaired (suggests dementia)

---

## ðŸ©º DIFFERENTIAL DIAGNOSIS GUIDELINES

### Distinguishing Dementia from Delirium
**Inouye et al., *NEJM* 2006;354:1157-1165**

| Feature | Delirium | Dementia |
|---------|----------|----------|
| **Onset** | Acute (hours-days) | Insidious (months-years) |
| **Course** | Fluctuating | Progressive |
| **Consciousness** | Altered (reduced/heightened) | Alert until late stages |
| **Attention** | Markedly impaired | May be preserved early |
| **Reversibility** | Usually reversible | Usually irreversible |
| **Hallucinations** | Often visual, fleeting | Variable (visual in LBD) |

**Note**: Delirium and dementia can coexist

### Distinguishing Dementia from Depression ("Pseudodementia")
**Butters et al., *J Int Neuropsychol Soc* 2008;14:556-563**

| Feature | Depression | Dementia |
|---------|------------|----------|
| **Onset** | Relatively acute | Insidious |
| **Subjective complaints** | Prominent, detailed | Vague, minimized |
| **Effort on testing** | Variable, "don't know" answers | Tries hard, confabulates |
| **Memory** | Encoding and retrieval impaired | Encoding impaired, recognition poor |
| **Response to treatment** | Improves with antidepressants | Does not improve |
| **Progression** | Symptoms stable or improve | Progressive decline |

**Note**: Depression and dementia can coexist (common in AD)

### Mild Cognitive Impairment (MCI) Criteria
**Petersen et al., *Arch Neurol* 2001;58:1985-1992**

**Core criteria**:
1. Cognitive concern (patient, informant, or clinician)
2. Objective cognitive impairment (1-1.5 SD below age/education norms)
3. Preserved independence in functional abilities
4. Not demented

**Subtypes**:
- **Amnestic MCI** (single or multiple domain): High risk for AD
- **Non-amnestic MCI** (single or multiple domain): Risk for FTD, DLB, VaD

**Progression**: ~10-15% per year convert to dementia (varies by subtype)

---

## ðŸ“– RECOMMENDED TEXTBOOKS AND RESOURCES

### Clinical Practice Guidelines
1. **American Academy of Neurology** - Practice parameters for diagnosis and evaluation of dementia
2. **NICE Guidelines (UK)** - Dementia: assessment, management and support (NG97)
3. **AGS/NIA Clinical Practice Guidelines** - Persistent and evaluating cognitive impairment in older adults

### Comprehensive Textbooks
1. **Budson & Solomon** - *Memory Loss, Alzheimer's Disease, and Dementia* (2nd Ed, 2022)
2. **Rabins et al.** - *Practical Dementia Care* (3rd Ed, 2017)
3. **Ames et al.** - *Neuropsychiatric Assessment* (2nd Ed, 2010)

### Online Resources
- **Alzheimer's Association** (alz.org): Clinical resources, criteria, patient education
- **NIA Alzheimer's Disease Education and Referral Center** (nia.nih.gov/alzheimers)
- **DementiaNet** (dementia.theclinics.com): Evidence-based guidelines
- **UpToDate**: Clinical decision support for dementia diagnosis and management

---

## ðŸ”¬ SPECIALIZED GUIDELINES BY DEMENTIA TYPE

### Alzheimer's Disease
- Jack CR, et al. *Alzheimer's Dement* 2018;14:535-562 (NIA-AA Research Framework)
- Dubois B, et al. *Lancet Neurol* 2014;13:614-629 (IWG-2 criteria)

### Vascular Dementia
- Gorelick PB, et al. *Stroke* 2011;42:2672-2713 (AHA/ASA Statement)
- Sachdev P, et al. *Alzheimer's Dement* 2014;10:266-281 (Diagnostic criteria)

### Lewy Body Dementia
- McKeith IG, et al. *Neurology* 2017;89:88-100 (Consensus criteria)
- Boot BP, et al. *Neurology* 2013;81:1552-1558 (Clinical features)

### Frontotemporal Dementia
- Rascovsky K, et al. *Brain* 2011;134:2456-2477 (bvFTD criteria)
- Gorno-Tempini ML, et al. *Neurology* 2011;76:1006-1014 (PPA classification)

### Mixed Dementia
- Schneider JA, et al. *JAMA Neurol* 2007;64:1066-1073 (Neuropathology studies)
- Jellinger KA & Attems J. *J Neurol Sci* 2010;299:143-148 (Prevalence and overlap)

---

## ðŸ“ ASSESSMENT TOOLS AND SCALES

### Cognitive Screening
- **MMSE**: 5-10 minutes, widely used, copyright restrictions
- **MoCA**: 10 minutes, free, more sensitive for MCI, www.mocatest.org
- **SLUMS** (St. Louis University Mental Status): Alternative to MMSE, free
- **Mini-Cog**: 3-minute screening (3-word recall + clock draw)

### Comprehensive Neuropsychological Batteries
- **Repeatable Battery for Assessment of Neuropsychological Status (RBANS)**
- **Consortium to Establish a Registry for Alzheimer's Disease (CERAD)**
- **Uniform Data Set (UDS)** - Used by ADCs

### Functional Assessment
- **Katz ADL Scale**
- **Lawton IADL Scale**
- **Functional Activities Questionnaire (FAQ)**
- **ADCS-ADL** (Alzheimer's Disease Cooperative Study ADL)

### Behavioral Assessment
- **Neuropsychiatric Inventory (NPI)**
- **Cohen-Mansfield Agitation Inventory (CMAI)**
- **Cornell Scale for Depression in Dementia**

---

## ðŸŽ¯ KEY TAKEAWAYS FOR ADRD CLASSIFICATION

1. **Apply formal diagnostic criteria** (NIA-AA, DSM-5, consensus criteria)
2. **Consider biomarkers** when available (CSF, PET imaging)
3. **Assess all cognitive domains** systematically (memory, language, executive, visuospatial)
4. **Evaluate functional status** - distinguishes dementia from MCI (ADL/IADL impairment required)
5. **Rule out reversible causes** - B12, thyroid, metabolic, medications, depression
6. **Identify progression pattern** - insidious (AD), stepwise (VaD), fluctuating (LBD)
7. **Recognize dementia subtypes** - specific features for AD, VaD, LBD, FTD
8. **Document confidence level** - high/moderate/low based on data completeness
9. **Consider mixed pathology** - common in elderly (AD + vascular)
10. **Longitudinal assessment** - single time point vs documented decline over time

---

*This resource guide should be used in conjunction with clinical judgment and up-to-date medical literature. Guidelines evolve as new evidence emerges.*
